China Approves Sanofi-Licensed Medicines Myqorzo and Redemplo, Expanding Treatment Options for Rare and Complex Diseases China’s National Medical Products Administration (NMPA) has granted regulatory approval to two innovative medicines licensed by Sanofi—Myqorzo (aficamten) and Redemplo (plozasiran). The approvals mark an…
Johnson & Johnson Launches Arbrea Breast Simulator Surgeon App for Mentor in the U.S. Johnson & Johnson has announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation tool designed to support plastic surgeons…
Johnson & Johnson Announces Positive Phase 3 Results for TECVAYLI® Monotherapy in Early Relapse Multiple Myeloma Johnson & Johnson a global leader in oncology innovation and multiple myeloma treatment, has announced encouraging topline results from the Phase 3 MajesTEC-9 clinical…
Alnylam Pharmaceuticals, Inc., the global leader in RNA interference (RNAi) therapeutics, has announced the launch of its new five-year corporate strategy, “Alnylam 2030,” outlining an ambitious roadmap to scale operations, strengthen leadership in transthyretin (ATTR) amyloidosis, advance a diversified pipeline…
argenx SE a global immunology company focused on developing innovative therapies for patients with severe autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for VYVGART® (intravenous…
Inside a laboratory in Cambridge, Massachusetts, Shawn Walker, Global Head of Synthetic Chemistry, Manufacturing and Controls (CMC) Development, gestures toward one of his most distinctive team members. Known as “Solutron,” the system is a sophisticated network of robotic arms, joints,…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has released a comprehensive set of business and pipeline updates ahead of its scheduled investor meetings in January, underscoring strong commercial momentum and continued advancement across its research and development portfolio. These updates will be…
Pfizer Inc has announced encouraging new clinical data from Cohort 3 of the pivotal Phase 3 BREAKWATER trial, reinforcing the potential of its targeted therapy BRAFTOVI® (encorafenib) to improve outcomes for patients with previously untreated metastatic colorectal cancer (mCRC) harboring…
Thermo Fisher Scientific Inc. a global leader in serving science, has announced a strategic collaboration with NVIDIA aimed at advancing the use of artificial intelligence (AI) across scientific instrumentation and laboratory operations. This partnership brings together Thermo Fisher’s extensive portfolio…
FDA Accepts Merck’s New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor Merck, a global leader in science and technology, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pimicotinib,…